Kras Mutant Genetically Engineered Mouse Models of Human Cancers
Kras mutant genetically engineered mouse models of PNAS PLUS human cancers are genomically heterogeneous Wei-Jen Chunga,1,2, Anneleen Daemena,1, Jason H. Chengb, Jason E. Longb, Jonathan E. Cooperb, Bu-er Wangb, Christopher Tranb, Mallika Singhb,3, Florian Gnada,4, Zora Modrusanc, Oded Foremand, and Melissa R. Junttilab,5 aBioinformatics & Computational Biology, Genentech, Inc., South San Francisco, CA 94080; bTranslational Oncology, Genentech, Inc., South San Francisco, CA 94080; cMolecular Biology, Genentech, Inc., South San Francisco, CA 94080; and dPathology, Genentech, Inc., South San Francisco, CA 94080 Edited by Anton Berns, The Netherlands Cancer Institute, Amsterdam, The Netherlands, and approved November 6, 2017 (received for review May 23, 2017) KRAS mutant tumors are largely recalcitrant to targeted therapies. treatment susceptibility and tumor evolution under selective pres- Genetically engineered mouse models (GEMMs) of Kras mutant sure of drug therapy. cancer recapitulate critical aspects of this disease and are widely used for preclinical validation of targets and therapies. Through Results comprehensive profiling of exomes and matched transcriptomes Spontaneous Acquisition of Genomic Aberrations in KrasG12D-Initiated of >200 KrasG12D-initiated GEMM tumors from one lung and two GEMM Tumors. To better define the genomic landscape of estab- pancreatic cancer models, we discover that significant intratumoral lished Kras mutant tumor models, we focused on three models of and intertumoral genomic heterogeneity evolves during tumorigen- Kras mutant cancer: a nonsmall cell lung cancer (NSCLC) model esis. Known oncogenes and tumor suppressor genes, beyond those with adenovirus-induced expression of KrasG12D and homozygous engineered, are mutated, amplified, and deleted. Unlike human tu- p53 targeting (KP:KrasLSL.G12D/wt;p53frt/frt) (11, 13), and two models mors, the GEMM genomic landscapes are dominated by copy num- ber alterations, while protein-altering mutations are rare.
[Show full text]